- Home
- TPST vs QCLS Comparison
TPST vs QCLS Comparison
Compare TPST & QCLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | QCLS |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 31.1M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | TPST | QCLS |
|---|---|---|
| Price | $1.05 | $3.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 98.1K | ★ 219.3K |
| Earning Date | 05-08-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $295,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $2.50 |
| 52 Week High | $12.22 | $8.17 |
Technical Indicators
Market Signals| Indicator | TPST | QCLS |
|---|---|---|
| Relative Strength Index (RSI) | 37.28 | 39.02 |
| Support Level | $1.02 | $3.42 |
| Resistance Level | $2.48 | $3.90 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 51.94 | 10.00 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
About QCLS Q/C Technologies Inc.
Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.